Growth prospects that even some Big Pharmas may envy
16/02/26 -"While we have raised our target price, the upside in Sandoz remains limited. Sandoz’s shares are valued at a massive premium to most of its listed peers, and this is why we consider ‘capitalising on ..."
Pages
49
Language
English
Published on
16/02/26
You may also be interested by these reports :
18/02/26
After Bayer announced that it will settle most of the Roundup (glyphosate; herbicide) related class action suits (alleging Non-Hodgkin’s lymphoma, a ...
18/02/26
Genmab’s full-year 2025 results showed both sales and adjusted operating profit falling short of market expectations. Despite this, double-digit ...
18/02/26
A Surprising Tactical Error by the Board
16/02/26
While we have raised our target price, the upside in Sandoz remains limited. Sandoz’s shares are valued at a massive premium to most of its listed ...